
Ultimovacs Q2 2023 - Minor trial delays but investment case intact

Redeye comments on Ultimovacs' Q2 2023 report, following a quarter in which the company's share price took a hit due to inconclusive NIPU top-line data. We judge INITIUM top-line data in H1 2024e and more detailed NIPU data in Q4 2023e could provide critical catalysts for the share. We make minor changes in our valuation model.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ultimovacs Q2 2023 - Minor trial delays but investment case intact](#)